In the ever-evolving landscape of pharmaceutical research, the quest for developing safer and more effective drugs is a continuous endeavor. Two crucial pillars in this journey are PBPK (physiologically-based pharmacokinetic) modeling and ADMET (Absorption, Distribution, Metabolism, Excretion and Toxicity) experimentation. Alone, each of these approaches plays a significant role in drug development, but their true potential is realized when they work hand in hand. PhinC Development (PhinC) and Oncodesign Services (ODS) are joining forces in order to provide valuable data. We’ve asked our experts what this partnership means to them.
